Sequencing of New Biologics and Targeted Synthetic DMARD’s

Director of Clinical Rheumatology
Baylor Research Institute
Professor of Medicine and Rheumatology
Baylor University Medical Center
Dallas, TX

Credits: 0.5

Release Date: May 13, 2019

Expiration Date: May 13, 2020

*This program has expired. CME credit is no longer available.

Target Audience:This activity has been designed to meet the educational needs of rheumatologists, physicians, physician assistants, and nurse practitioners involved in the care of patients with psoriatic disease.

Learning Objectives: After the completion of this activity, participants should be able to:

  • Recognize equivalent efficacy of triple DMARD therapy vs MTX plus TNF inhibitor
  • Assess different approaches to managing anti-TNF cycling vs. switching to a different mechanism of action agent
  • Understand the difference between primary and secondary non-responders
  • Explain which therapies are more effective in seropositive RA patients
  • STATEMENT OF SUPPORT: This activity is supported by educational grants from AbbVie, Amgen, Bristol-Myers Squibb, Janssen Biotech, Inc., Lilly, and Sandoz Inc., A Novartis Division

    PHYSICIAN ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Focus Medical Communications. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

    CREDIT DESIGNATION: Purdue University College of Pharmacy designates this enduring activity for a maximum of
    0.5 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This program has been approved for 0.5 contact hours.

    DISCLOSURE STATEMENT: All faculty and staff involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

    All additional planning committee members, reviewers and Purdue University College of Pharmacy and Focus Medical Communications staff have no relationships to disclose.

    John J. Cush, MD
    Dr. Cush has been a clinical investigator for AbbVie Inc., Astra-Zeneca, Celgene, Genentech, Inc., Janssen Biotech Inc., Novartis and Pfizer. He has been a consultant and/or advisor for AbbVie Inc., Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Inc., Horizon Pharma, Lilly, Novartis and UCB Inc.